(Q24641848)

English

High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

0 references

High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller (English)

0 references

1 reference

based on heuristic

inferred from title

Martine Piccart-Gebhart

17

object named as

Martine Piccart-Gebhart

0 references

Fátima Cardoso

object named as

Fatima Cardoso

6

0 references

Funda Meric-Bernstam

4

object named as

Funda Meric-Bernstam

0 references

Ana Maria Gonzalez-Angulo

1

object named as

Ana M Gonzalez-Angulo

0 references

Gabriel N Hortobagyi

20

object named as

Gabriel N Hortobagyi

0 references

author name string

Jennifer K Litton

2

0 references

Kristine R Broglio

3

0 references

Ronjay Rakkhit

5

0 references

Florentia Peintinger

7

0 references

Emer O Hanrahan

8

0 references

Aysegul Sahin

9

0 references

Merih Guray

10

0 references

Denis Larsimont

11

0 references

Francesco Feoli

12

0 references

Heidi Stranzl

13

0 references

Thomas A Buchholz

14

0 references

Vicente Valero

15

0 references

Richard Theriault

16

0 references

Peter M Ravdin

18

0 references

Donald A Berry

19

0 references

language of work or name

0 references

publication date

1 December 2009

0 references

Journal of Clinical Oncology

0 references

27

0 references

34

0 references

5700-6

0 references

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2792998

7 April 2017

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2792998

7 April 2017

American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2792998

7 April 2017

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2792998

7 April 2017

Trastuzumab--mechanism of action and use in clinical practice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2792998

7 April 2017

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2792998

7 April 2017

Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2792998

27 September 2017

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2792998

27 September 2017

The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: A paradigm for the development of other macromolecular markers-A review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2792998

27 September 2017

Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2792998

28 November 2018

Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2792998

28 November 2018

Identifiers

10.1200/JCO.2009.23.2025

0 references

PMC publication ID

0 references

PubMed publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q24641848&oldid=1954284550"